KAMADA LTD (KMDA) Stock Fundamental Analysis
NASDAQ:KMDA - Nasdaq - IL0010941198 - Common Stock - Currency: USD
Taking everything into account, KMDA scores 6 out of 10 in our fundamental rating. KMDA was compared to 551 industry peers in the Biotechnology industry. While KMDA belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. KMDA is valued quite cheap, while showing a decent growth score. This is a good combination! This makes KMDA very considerable for value investing!
1. Profitability
1.1 Basic Checks
KMDA had positive earnings in the past year.
In the past year KMDA had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: KMDA reported negative net income in multiple years.
Of the past 5 years KMDA 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of KMDA (4.28%) is better than 91.83% of its industry peers.
KMDA's Return On Equity of 6.37% is amongst the best of the industry. KMDA outperforms 93.10% of its industry peers.
The Return On Invested Capital of KMDA (5.91%) is better than 93.28% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for KMDA is significantly below the industry average of 14.91%.
The last Return On Invested Capital (5.91%) for KMDA is above the 3 year average (2.98%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.28% | ||
| ROE | 6.37% | ||
| ROIC | 5.91% |
ROA(3y)1.84%
ROA(5y)2.59%
ROE(3y)2.55%
ROE(5y)3.2%
ROIC(3y)2.98%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 9.60%, KMDA belongs to the best of the industry, outperforming 92.92% of the companies in the same industry.
In the last couple of years the Profit Margin of KMDA has declined.
The Operating Margin of KMDA (14.24%) is better than 94.56% of its industry peers.
In the last couple of years the Operating Margin of KMDA has declined.
KMDA's Gross Margin of 44.23% is fine compared to the rest of the industry. KMDA outperforms 75.14% of its industry peers.
In the last couple of years the Gross Margin of KMDA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 14.24% | ||
| PM (TTM) | 9.6% | ||
| GM | 44.23% |
OM growth 3YN/A
OM growth 5Y-7.02%
PM growth 3YN/A
PM growth 5Y-12.51%
GM growth 3Y14.12%
GM growth 5Y2.16%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), KMDA is destroying value.
Compared to 1 year ago, KMDA has about the same amount of shares outstanding.
Compared to 5 years ago, KMDA has more shares outstanding
Compared to 1 year ago, KMDA has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.98 indicates that KMDA is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.98, KMDA is in the better half of the industry, outperforming 72.96% of the companies in the same industry.
KMDA has a debt to FCF ratio of 0.30. This is a very positive value and a sign of high solvency as it would only need 0.30 years to pay back of all of its debts.
KMDA has a Debt to FCF ratio of 0.30. This is amongst the best in the industry. KMDA outperforms 95.64% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that KMDA is not too dependend on debt financing.
KMDA has a Debt to Equity ratio of 0.04. This is in the lower half of the industry: KMDA underperforms 60.98% of its industry peers.
Although KMDA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | 0.3 | ||
| Altman-Z | 2.98 |
ROIC/WACC0.66
WACC8.97%
2.3 Liquidity
KMDA has a Current Ratio of 3.30. This indicates that KMDA is financially healthy and has no problem in meeting its short term obligations.
KMDA has a worse Current ratio (3.30) than 61.34% of its industry peers.
KMDA has a Quick Ratio of 1.93. This is a normal value and indicates that KMDA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.93, KMDA is doing worse than 75.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.3 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
KMDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.09%, which is quite impressive.
Measured over the past years, KMDA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.60% on average per year.
Looking at the last year, KMDA shows a quite strong growth in Revenue. The Revenue has grown by 11.83% in the last year.
Measured over the past years, KMDA shows a small growth in Revenue. The Revenue has been growing by 4.82% on average per year.
EPS 1Y (TTM)26.09%
EPS 3YN/A
EPS 5Y-13.6%
EPS Q2Q%75%
Revenue 1Y (TTM)11.83%
Revenue growth 3Y15.82%
Revenue growth 5Y4.82%
Sales Q2Q%16.65%
3.2 Future
KMDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.03% yearly.
KMDA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.00% yearly.
EPS Next Y28.48%
EPS Next 2Y24.22%
EPS Next 3Y28.03%
EPS Next 5YN/A
Revenue Next Year12.1%
Revenue Next 2Y10.7%
Revenue Next 3Y9%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 24.79 indicates a rather expensive valuation of KMDA.
93.83% of the companies in the same industry are more expensive than KMDA, based on the Price/Earnings ratio.
KMDA's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.24.
With a Price/Forward Earnings ratio of 17.92, KMDA is valued on the expensive side.
93.28% of the companies in the same industry are more expensive than KMDA, based on the Price/Forward Earnings ratio.
KMDA is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.42, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.79 | ||
| Fwd PE | 17.92 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of KMDA indicates a rather cheap valuation: KMDA is cheaper than 97.28% of the companies listed in the same industry.
KMDA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. KMDA is cheaper than 96.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.32 | ||
| EV/EBITDA | 9.22 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KMDA may justify a higher PE ratio.
A more expensive valuation may be justified as KMDA's earnings are expected to grow with 28.03% in the coming years.
PEG (NY)0.87
PEG (5Y)N/A
EPS Next 2Y24.22%
EPS Next 3Y28.03%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 2.77%, KMDA has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 126.79, KMDA pays a better dividend. On top of this KMDA pays more dividend than 98.55% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, KMDA has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.77% |
5.2 History
KMDA does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y24.22%
EPS Next 3Y28.03%
7.19
-0.03 (-0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners10.27%
Inst Owner Change5.01%
Ins Owners2.34%
Ins Owner ChangeN/A
Market Cap413.50M
Analysts84.44
Price Target15.05 (109.32%)
Short Float %0.29%
Short Ratio1.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.77% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.18%
Min EPS beat(2)1.67%
Max EPS beat(2)28.68%
EPS beat(4)4
Avg EPS beat(4)17.92%
Min EPS beat(4)1.67%
Max EPS beat(4)38.4%
EPS beat(8)7
Avg EPS beat(8)38.21%
EPS beat(12)9
Avg EPS beat(12)-12.84%
EPS beat(16)9
Avg EPS beat(16)-100.15%
Revenue beat(2)1
Avg Revenue beat(2)-0.44%
Min Revenue beat(2)-3.06%
Max Revenue beat(2)2.19%
Revenue beat(4)2
Avg Revenue beat(4)1%
Min Revenue beat(4)-3.06%
Max Revenue beat(4)4.89%
Revenue beat(8)3
Avg Revenue beat(8)0.32%
Revenue beat(12)4
Avg Revenue beat(12)-0.47%
Revenue beat(16)5
Avg Revenue beat(16)-0.1%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20%
EPS NY rev (1m)10.08%
EPS NY rev (3m)10.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.79 | ||
| Fwd PE | 17.92 | ||
| P/S | 2.47 | ||
| P/FCF | 11.32 | ||
| P/OCF | 8.98 | ||
| P/B | 1.64 | ||
| P/tB | 1.87 | ||
| EV/EBITDA | 9.22 |
EPS(TTM)0.29
EY4.03%
EPS(NY)0.4
Fwd EY5.58%
FCF(TTM)0.64
FCFY8.84%
OCF(TTM)0.8
OCFY11.14%
SpS2.91
BVpS4.38
TBVpS3.85
PEG (NY)0.87
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.28% | ||
| ROE | 6.37% | ||
| ROCE | 7.49% | ||
| ROIC | 5.91% | ||
| ROICexc | 7.78% | ||
| ROICexgc | 8.89% | ||
| OM | 14.24% | ||
| PM (TTM) | 9.6% | ||
| GM | 44.23% | ||
| FCFM | 21.85% |
ROA(3y)1.84%
ROA(5y)2.59%
ROE(3y)2.55%
ROE(5y)3.2%
ROIC(3y)2.98%
ROIC(5y)N/A
ROICexc(3y)3.78%
ROICexc(5y)N/A
ROICexgc(3y)8.93%
ROICexgc(5y)N/A
ROCE(3y)3.78%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-12.12%
ROICexc growth 3YN/A
ROICexc growth 5Y-24.72%
OM growth 3YN/A
OM growth 5Y-7.02%
PM growth 3YN/A
PM growth 5Y-12.51%
GM growth 3Y14.12%
GM growth 5Y2.16%
F-Score6
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | 0.3 | ||
| Debt/EBITDA | 0.25 | ||
| Cap/Depr | 67.17% | ||
| Cap/Sales | 5.7% | ||
| Interest Coverage | 37.14 | ||
| Cash Conversion | 121.25% | ||
| Profit Quality | 227.48% | ||
| Current Ratio | 3.3 | ||
| Quick Ratio | 1.93 | ||
| Altman-Z | 2.98 |
F-Score6
WACC8.97%
ROIC/WACC0.66
Cap/Depr(3y)51.63%
Cap/Depr(5y)66.68%
Cap/Sales(3y)4.57%
Cap/Sales(5y)4.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)26.09%
EPS 3YN/A
EPS 5Y-13.6%
EPS Q2Q%75%
EPS Next Y28.48%
EPS Next 2Y24.22%
EPS Next 3Y28.03%
EPS Next 5YN/A
Revenue 1Y (TTM)11.83%
Revenue growth 3Y15.82%
Revenue growth 5Y4.82%
Sales Q2Q%16.65%
Revenue Next Year12.1%
Revenue Next 2Y10.7%
Revenue Next 3Y9%
Revenue Next 5YN/A
EBIT growth 1Y72.33%
EBIT growth 3YN/A
EBIT growth 5Y-2.54%
EBIT Next Year111.37%
EBIT Next 3Y35.88%
EBIT Next 5YN/A
FCF growth 1Y130.07%
FCF growth 3YN/A
FCF growth 5Y7.84%
OCF growth 1Y127.24%
OCF growth 3YN/A
OCF growth 5Y11.54%